Saw Palmetto Complex
Natural health product licensed in Canada
- Licence holder
- SISU
- NPN or DIN-HM
- 80006719
- Status
- Inactive licence
- Licence date
- 21 July 2008
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Urtica dioica L.: L'étiquetage des compléments alimentaires contenant les parties souterraines de cette plante doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Serenoa repens Source : Fruit(s) Extraction ratio : 4:1 Dry plant equivalent : 500 mg Potency : 20 % Fatty acids | 125 mg | Not calculated |
| Urtica dioica Source : Racine | 75 mg | Not calculated |
| Pygeum africanum Source : Écorce Extraction ratio : 30:1 Dry plant equivalent : 750 mg | 25 mg | Not calculated |
| Uva-ursi Source : Feuille(s) Extraction ratio : 4:1 Dry plant equivalent : 60 mg Potency : 10 % Arbutin | 15 mg | Not calculated |
Non-medicinal ingredients
Gélatine, Dioxyde de silicium, Stéarate de magnésium, Cellulose - microcrystalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 3 Capsule | 2 Tous les jours |
Uses authorised in Canada
Acts as a supportive therapy for the treatment of symptoms of Benign Prostatic Hyperplasia (BPH).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you are taking medication for diabetes and/or blood thinners. Do not use if you have hypotension or hypertension. Do not use if you are pregnant or breastfeeding. Should not be taken with any substance that causes acidic urine.
Source
Official Health Canada record, licence 80006719
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.